INSV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INSV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-24), InSite Vision's share price is $0.3475. InSite Vision's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2015 was $-0.09. Hence, InSite Vision's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for InSite Vision's Price-to-Free-Cash-Flow or its related term are showing as below:
InSite Vision's Free Cash Flow per Share for the three months ended in Jun. 2015 was $-0.04. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.09.
The historical data trend for InSite Vision's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSite Vision Annual Data | |||||||||||||||||||||
Trend | Dec05 | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | |||||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | 4.17 | - |
InSite Vision Quarterly Data | ||||||||||||||||||||
Sep10 | Dec10 | Mar11 | Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Drug Manufacturers - Specialty & Generic subindustry, InSite Vision's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, InSite Vision's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where InSite Vision's Price-to-Free-Cash-Flow falls into.
InSite Vision's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 0.3475 | / | -0.086 | |
= | N/A |
InSite Vision's Share Price of today is $0.3475.
InSite Vision's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
InSite Vision (OTCPK:INSV) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of InSite Vision's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Louis Drapeau | officer: Vice President and CFO | C/O BIOMARIN PHARMACEUTICAL INC., 371 BEL MARIN KEYS BLVD., SUITE 210, NOVATO CA 94949 |
Brian Levy | director | |
Anthony J Yost | director | C/O INSITE VISION, INC., 965 ATLANTIC AVENUE, ALAMEDA CA 94501 |
Timothy Mcinerney | director | |
Craig A Tooman | director | |
Coliseum Capital Management, Llc | 10 percent owner | 105 ROWAYTON AVENUE, ROWAYTON CT 06853 |
Timothy P Lynch | director | 919 NW BOND STREET, SUITE 204, BEND OR 97703 |
Rick D Anderson | director | 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746 |
Jon S Saxe | director | FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076 |
Francis Wen-hou Chen | director | 1821 JONES STREET, SAN FRANCISCO CA 94109 |
Pinto Tv Gp Co Llc | 10 percent owner | 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746 |
Matthew S Crawford | 10 percent owner | 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746 |
Pfizer Inc | 10 percent owner | 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.